Position in BBIO
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$4,863,544
+$14,366 QoQ
Shares Held
65,300
0.0% QoQ
Ownership
0.033%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#153
of 473 holders
Holding Since
Mar 2021
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BBIO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GABELLI FUNDS LLC holds $57,008,523 across 31 Biotechnology names. BBIO ranks #3 (8.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
127,281 | $16,894,007 | |
| 2 | TECH |
BIO-TECHNE Corp
|
189,300 | $13,374,045 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
This page
|
65,300 | $4,863,544 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,891 | $3,919,696 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
46,200 | $3,616,074 | |
| 6 | MRNA |
Moderna, Inc.
|
29,500 | $2,065,885 | |
| 7 | INCY |
Incyte Corp
|
14,197 | $1,609,371 | |
| 8 | ABVX |
Abivax S.A.
|
10,000 | $1,332,600 |
All Filings in BBIO
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,863,544 | 65,300 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $4,849,178 | 65,300 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $4,723,257 | 61,750 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $3,804,605 | 73,250 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $3,184,525 | 73,750 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $2,540,895 | 73,500 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $2,016,840 | 73,500 | Shares | Sole | 2025-02-13 | |
| 2021-09-30 | $281,220 | 6,000 | Shares | Sole | 2021-11-12 | |
| 2021-06-30 | $518,160 | 8,500 | Shares | Sole | 2021-08-13 | |
| 2021-03-31 | $782,320 | 12,700 | Shares | Sole | 2021-05-14 | |
| No filing history on record for this holder in this stock. | ||||||